[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity

Rhea-AI Filing Summary

BridgeBio Pharma (NASDAQ: BBIO) filed a Form 4 disclosing that director Frank P. McCormick sold 100,000 common shares on 06/24/2025 under a pre-arranged Rule 10b5-1 plan.

The shares were sold at a weighted-average price of $44.23, generating proceeds of roughly $4.4 million.

Following the sale, McCormick owns 879,979 shares indirectly through his revocable trust and 83,275 shares directly, implying the transaction reduced his total position by about 9-10%.

No derivative securities were involved and no other insiders were party to the filing.

Insights

Insider Transactions Analyst

TL;DR: Large director sale (~$4.4 M) trims stake 10%, modest bearish read-through.

The 100 k-share disposal exceeds the $1 M materiality threshold and represents roughly one-tenth of McCormick’s holdings, flagging a potential sentiment shift. Although executed via a 10b5-1 plan—partly mitigating interpretation of opportunistic timing—the magnitude is notable for a scientific founder-director whose ownership has signalled long-term alignment. Investors often discount 10b5-1 sales, yet repeated or accelerating disposals could pressure perception, especially ahead of pivotal clinical catalysts. No offsetting insider purchases are disclosed, so near-term optics skew negative.

Corporate Governance Specialist

TL;DR: Pre-planned trade limits governance concern; watch cadence of future sales.

The filing confirms compliance with Section 16 reporting and Rule 10b5-1 safeguards, reducing legal or policy risk. The trust’s remaining 880 k shares still align the director’s economic interests with shareholders. However, a single sizable sale can trigger proxy-advisory scrutiny if followed by attendance issues or compensation votes. Given his continuing role and sizable residual stake, governance impact is limited today, but tracking pattern frequency will be key for evaluating board commitment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCCORMICK FRANK

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/24/2025		S(1)		100,000	D	$44.228(2)	879,979	I	By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Common Stock								83,275	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 28, 2024.

2. Represents the weighted average sale price of the shares sold from $44.00 to $44.69 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

	/s/ Dr. Francis P. McCormick	06/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.